APC Annexin V Apoptosis Detection Kit with 7-AAD

Pricing & Availability
Regulatory Status
Other Names
Annexin A5 Apoptosis Detection Kit
Ave. Rating
Submit a Review
Product Citations
Human T-cell leukemia cell line, Jurkat, treated (top) or non-treated (bottom) with LEAF™ purified anti-human CD95 (clone EOS9.1) for 4 hours, then stained with APC Annexin V Apoptosis Detection Kit with 7-AAD.
  • Annexin-V_APC-7AAD_Antibody_FC_1_050714.jpg
    Human T-cell leukemia cell line, Jurkat, treated (top) or non-treated (bottom) with LEAF™ purified anti-human CD95 (clone EOS9.1) for 4 hours, then stained with APC Annexin V Apoptosis Detection Kit with 7-AAD.
  • Annexin-V_APC-7AAD_Antibody_FC_2_050714.jpg
See APC spectral data
Cat # Size Price Quantity Check Availability Save
640930 100 tests £183
Check Availability

Need larger quantities of this item?
Request Bulk Quote

BioLegend's APC Annexin V Apoptosis Detection Kit with 7-AAD has been specifically designed for the identification of apoptotic and necrotic cells.

Annexin V (or Annexin A5) is a member of the annexin family of intracellular proteins that binds to phosphatidylserine (PS) in a calcium-dependent manner. PS is normally only found on the intracellular leaflet of the plasma membrane in healthy cells, but during early apoptosis, membrane asymmetry is lost and PS translocates to the external leaflet. Fluorochrome-labeled Annexin V can then be used to specifically target and identify apoptotic cells. Annexin V Binding Buffer is recommended for use with Annexin V staining. Annexin V binding alone cannot differentiate between apoptotic and necrotic cells. To help distinguish between the necrotic and apoptotic cells we recommend use of our 7-amino-actinomycin D (7-AAD) solution. Early apoptotic cells will exclude 7-AAD, while late stage apoptotic cells will stain positively, due to the passage of these dyes into the nucleus where they bind to DNA.

7-AAD (7-amino-actinomycin D) has a high DNA binding constant and is efficiently excluded by intact cells. It is useful for DNA analysis and dead cell discrimination during flow cytometric analysis. When excited by 488 laser light, 7-AAD fluorescence is detected in the far red range of the spectrum (650 nm long-pass filter).

Product Details
Technical Data Sheet (pdf)

Product Details

Verified Reactivity
All mammalian species
Lot-specific (to obtain lot-specific concentration, please enter the lot number in our Concentration and Expiration Lookup or Certificate of Analysis online tools.)
Storage & Handling
Store between 2°C and 8°C. Do not freeze.

Caution: 7-AAD is a potential carcinogen. It is recommended that the user wear protective clothing, gloves, and eye/face protection in order to avoid contact with skin and eyes.

FC - Quality tested

Recommended Usage

Staining Procedure:
1. Wash cells twice with cold BioLegend's Cell Staining Buffer, and then resuspend cells in Annexin V Binding Buffer at a concentration of 0.25-1.0 x 107 cells/mL.
2. Transfer 100 µL of cell suspension in a 5 mL test tube.
3. Add 5 µL of APC Annexin V.
4. Add 5 µL of 7-AAD Viability Staining Solution.
5. Gently vortex the cells and incubate for 15 min at room temperature (25°C) in the dark.
6. Add 400 µL of Annexin V Binding Buffer to each tube. Analyze by flow cytometry with proper machine settings.

Excitation Laser
Red Laser (633 nm)
Application Notes

Materials Provided:
0.5 ml of APC Annexin V
0.5 ml of 7-AAD Viability Staining Solution
50 ml of Annexin V Binding Buffer

Materials Not Included:
Cell Staining Buffer (Cat. No. 420201)

For a better experience detecting apoptosis, we now recommend Apotracker™. Cell staining with Apotracker™ is Calcium independent. Thus, no special buffers are required, and the protocol can be shortened for single-step co-staining with other reagents.

Application References

(PubMed link indicates BioLegend citation)
  1. Maciel E, et al. 2014. Arch Biochem Biophys. 548:38. PubMed
Product Citations
  1. Català C, et al. 2022. iScience. 25:105078. PubMed
  2. Rutherford TR, et al. 2021. Cell Death Dis. 12:872. PubMed
  3. Chiarella E, et al. 2020. Heliyon. 6:e04020. PubMed
  4. Chen CC, et al. 2020. Cancer Cell. 37:71. PubMed
  5. Paz H, et al. 2018. J Exp Clin Cancer Res. 37:67. PubMed
  6. Krone A, et al. 2022. Sci Rep. 218:. PubMed
  7. Fluckiger A, et al. 2016. Oncogene. 10.1038/onc.2015.523. PubMed
  8. Papadas A, et al. 2022. Cell Rep. 40:111201. PubMed
  9. Cribioli E, et al. 2022. Front Immunol. 13:976628. PubMed
  10. Huangfu J, et al. 2021. Cell Death Dis. 12:386. PubMed
  11. Li W, et al. 2022. PeerJ. 10:e14086. PubMed
  12. Wu L, et al. 2022. Theranostics. 12:842. PubMed
  13. Yao F, et al. 2021. Nat Commun. 12:7333. PubMed
  14. Lee A, et al. 2022. Int J Oncol. 60:. PubMed
  15. Chen X, et al. 2021. Theranostics. 11:3392. PubMed
  16. Gómez-Aleza C, et al. 2020. Nat Commun. 4.857638889. PubMed
  17. Broggi A, et al. 2017. Nat Immunol. 18:1084. PubMed
  18. Vogiatzi F, et al. 2022. Blood Adv. 6:4847. PubMed
  19. Xie J, et al. 2018. Oncol Lett. 16:157. PubMed
  20. Dong Y, et al. 2020. J Leukoc Biol. 108:1711. PubMed
  21. Li H,et al. 2017. Sci Rep.. 10.1038/s41598-017-13471-4. PubMed
  22. Zhuo J, et al. 2021. Cell Death Dis. 12:1084. PubMed
  23. Wu H, et al. 2021. Cell Death Discov. 7:225. PubMed
  24. Tang Q, et al. 2021. Genes Dev. 35:528. PubMed
  25. Lei J, et al. 2021. Theranostics. 4251:11. PubMed
  26. Tanaka T, et al. 2020. Sci Rep. 10:15169. PubMed
  27. Dolan M, et al. 2019. PLoS One. 14:e0220101. PubMed
  28. Hu M, et al. 2020. Cancer Immunol Res. 8:1150. PubMed
  29. Singh SK, et al. 2021. Oncogene. 40:6153. PubMed
  30. Wang Y, et al. 2022. Nat Commun. 13:6663. PubMed
  31. Gong H, et al. 2019. EBioMedicine. 44:138. PubMed
  32. Fragoso MF, et al. 2022. Int J Mol Sci. 23:. PubMed
  33. Yin S, et al. 2015. Sci Rep. 5: 14432. PubMed
  34. Gunda V, et al. 2020. Cancers (Basel). 12:00. PubMed
  35. Peeters R, et al. 2022. Nat Commun. 13:5371. PubMed
  36. Leary N, et al. 2022. J Extracell Vesicles. 11:e12197. PubMed
  37. Tang J, et al. 2021. Front Genet. 12:666451. PubMed
  38. Gourvest M, et al. 2021. Leukemia. . PubMed
  39. Riebeling T, et al. 2020. Cell Death Differ. . PubMed
  40. Tan H, et al. 2022. Acta Pharm Sin B. 12:2348. PubMed
  41. Huang Z, et al. 2021. Am J Cancer Res. 4287:10. PubMed
  42. Seong BKA, et al. 2021. Cancer Cell. 39:1262. PubMed
  43. Li K, et al. 2021. J Exp Med. 218:. PubMed
  44. Zhan L, et al. 2021. Exp Ther Med. 22:1082. PubMed
  45. Hezkiy EE, et al. 2022. Cells. 11:. PubMed
  46. Lei X, et al. 2022. Nat Commun. 13:3882. PubMed
  47. Jin X, et al. 2022. iScience. 25:104349. PubMed
  48. Simula L, et al. 2020. Cell Death Differ. 27:2749. PubMed
  49. Corso J, et al. 2016. Proc Natl Acad Sci U S A. 113: 5688 - 5693. PubMed

Antigen Details

Biology Area
Apoptosis/Tumor Suppressors/Cell Death, Cell Biology, Cell Proliferation and Viability, Neuroscience
Gene ID
308 View all products for this Gene ID

Related FAQs

How is your Annexin made and what sequence does it cover?

It is made in E. coli, covering human aa Met1-Asp320.

How does pH and staining temperature affect Annexin V-Phosphatidylserine binding?

Annexin-Phosphatidylserine binding is lost below pH 5.2 and with prolonged incubation over a temperature of 42°C.

Why do I need to use Annexin V Binding Buffer?

Annexin V binding requires the presence of calcium in the solution.  So, we provide Annexin V Binding Buffer (cat # 422201), which is optimized for the best performance of Annexin V staining.

Can I use RPMI during Annexin V staining?

It is best to follow protocol as described on the product data sheet. Moreover, RPMI 1640 has a relatively high concentration of phosphate and low calcium ion concentration, which negatively impacts Annexin binding to its target phosphatidylserine (PS). Measurement of cell death by using Annexin V may also be significantly affected by time of incubation on ice, calcium concentration, and type of medium.

Can I freeze Annexin V conjugates?

It should not be frozen as it will lead to loss of biological activity due to dimerization.

Is Annexin V suitable for conjugation with the Maxpar® kit for CyTOF®?

Maxpar® Labeling kits require the protein to be partially reduced, so the metal chelate can be introduced through an SH group in the hinge region of the reduced antibody. Human Annexin V contains only one Cysteine which was reported to be chemically inactive. Thus, the Maxpar® labeling protocol would not work with Annexin V, unless a free –SH group can be introduced to Annexin V.  For more information regarding SH-mediated conjugation of Annexin V please consult published papers such as this one.

Go To Top Version: 2    Revision Date: 04/20/2020

For research use only. Not for diagnostic use. Not for resale. BioLegend will not be held responsible for patent infringement or other violations that may occur with the use of our products.


*These products may be covered by one or more Limited Use Label Licenses (see the BioLegend Catalog or our website, www.biolegend.com/ordering#license). BioLegend products may not be transferred to third parties, resold, modified for resale, or used to manufacture commercial products, reverse engineer functionally similar materials, or to provide a service to third parties without written approval of BioLegend. By use of these products you accept the terms and conditions of all applicable Limited Use Label Licenses. Unless otherwise indicated, these products are for research use only and are not intended for human or animal diagnostic, therapeutic or commercial use.


8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.


Login / Register
Remember me
Forgot your password? Reset password?
Create an Account